ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Enhanced ocular delivery of brinzolamide via β-cyclodextrin-based micelles for glaucoma management.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brinzolamide (BRZ) is a carbonic anhydrase inhibitor for primary open-angle glaucoma (POAG) and ocular hypertension (OH). However, it suffers from poor aqueous solubility, leading to irritation and reduced patient compliance. This study introduces a novel β-cyclodextrin (β-CD)-based micellar formulation (MCLs) to improve solubility, safety, and therapeutic performance. BRZ micellar formulations (BRZ-MCLs) were developed using Pluronic F68/F127 and β-CD to enhance solubility. Characterization included particle size, polydispersity index (PDI), entrapment efficiency (EE%), and in vitro release. Irritation was assessed via HET-CAM (Hen's Egg Chorioallantoic Membrane) and Draize tests. Molecular docking (PDB ID: 4M2R) and TOPKAT predicted stable binding and favorable safety. The optimized BRZ-MCLs showed a particle size of 80 ± 7.7 nm, low PDI (0.145 ± 0.06), negative ZP (- 11.8 ± 0.21), and high EE% (81.95 ± 1.62%). They achieved sustained drug release (85 ± 0.275% over 72 h), significantly higher than the BRZ suspension (69 ± 0.202%). Molecular docking indicated stable BRZ binding with THR A: 200, PHE A:131, and PRO A:202. Toxicity assessments confirmed BRZ-MCLs were non-irritating (irritation score (IS) = 0) and non-mutagenic. This β-CD micellar system offers a novel, patient-friendly strategy for ocular BRZ delivery, addressing solubility and irritation issues while enhancing therapeutic outcomes in glaucoma management.
Indexed as
Identifiers
41283997What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.